Vanda Pharmaceuticals INC Form 4 insider transactions

Daniel Patrick McGuire, SVP, GC and Secretary of Vanda Pharmaceuticals, was granted 80,000 restricted stock units.

Phaedra Chrousos, a Director at Vanda Pharmaceuticals Inc., acquired 41,600 shares of common stock through a restricted stock unit award.

Vanda Pharmaceuticals Inc. reports a Form 4 filing detailing a director's acquisition of common stock underlying a restricted stock unit award.

Richard W. Dugan, a Director at Vanda Pharmaceuticals Inc., acquired 41,600 shares of common stock through a restricted stock unit award.

Vanda Pharmaceuticals Inc. Director Anne Sempowski Ward acquired 41,600 shares of common stock through a restricted stock unit award.

Tage Honore, a Director at Vanda Pharmaceuticals Inc., acquired 41,600 shares of common stock underlying a restricted stock unit award.

Vanda Pharmaceuticals Inc. director Stephen Ray Mitchell acquired 41,600 shares of common stock through a restricted stock unit award.

Vanda Pharmaceuticals Director Stephen Ray Mitchell reported a charitable gift of 25,836 shares of common stock.

Director Charles Cliff Duncan was granted 57,101 restricted stock units by Vanda Pharmaceuticals.

Vanda Pharmaceuticals' SVP & General Counsel, Timothy Williams, sold 42,434 shares of common stock to cover tax obligations from vested restricted stock units.

Vanda Pharmaceuticals' SVP, CFO & Treasurer, Kevin Patrick Moran, filed a Form 4 detailing a planned sale of 42,442 common shares on March 2, 2026, to cover tax obligations from vested RSUs.

Vanda Pharmaceuticals' SVP and Chief Marketing Officer, Joakim Wijkstrom, sold 30,800 shares of common stock to cover tax obligations related to vested restricted stock units.

Vanda Pharmaceuticals' President and CEO, Mihael H. Polymeropoulos, sold 156,235 shares of common stock to cover tax liabilities from vested restricted stock units.

Vanda Pharmaceuticals' SVP of Business Development, Gunther Birznieks, sold 42,431 shares of common stock to cover tax obligations related to vested restricted stock units.

Vanda Pharmaceuticals Inc. Director Tage Honore reported the sale of 30,000 shares of common stock at $8.03 per share.

Vanda Pharmaceuticals Inc. has granted 125,000 restricted stock units to Joakim Wijkstrom, SVP and Chief Marketing Officer, as part of his compensation.

Vanda Pharmaceuticals' SVP of Business Development, Gunther Birznieks, received 125,000 restricted stock units vesting over four years.

Vanda Pharmaceuticals Inc. granted 125,000 restricted stock units to SVP & General Counsel Timothy Williams, vesting over four years.

Vanda Pharmaceuticals' SVP, CFO & Treasurer, Kevin Patrick Moran, was granted 125,000 restricted stock units vesting over four years.

Vanda Pharmaceuticals' President and CEO, Mihael H. Polymeropoulos, received a significant restricted stock unit award, aligning executive interests with long-term shareholder value.

Vanda Pharmaceuticals Inc.'s President and CEO, Mihael H. Polymeropoulos, purchased 10,000 shares of common stock for $4.15 per share.

Stephen Ray Mitchell, a Director at Vanda Pharmaceuticals Inc., sold 7,000 shares of common stock for approximately $32,130 under a Rule 10b5-1 trading plan.

Vanda Pharmaceuticals Inc. Director Stephen Ray Mitchell was granted 59,225 restricted stock units (RSUs) on June 5, 2025, which are set to vest on June 5, 2026.

Phaedra Chrousos, a Director at Vanda Pharmaceuticals Inc., was granted 59,225 restricted stock units, increasing her total beneficial ownership to 123,350 shares.

Vanda Pharmaceuticals Inc. Director Richard W. Dugan was granted 59,225 restricted stock units (RSUs) on June 5, 2025, which are set to vest on June 5, 2026.

Vanda Pharmaceuticals Inc. Director Tage Honore was granted 59,225 restricted stock units, increasing his beneficial ownership to 123,469 shares, with vesting scheduled for June 5, 2026.

Vanda Pharmaceuticals Inc. Director Anne Sempowski Ward was granted 59,225 shares of common stock in the form of a restricted stock unit (RSU) award, vesting fully on June 5, 2026.

Mihael Hristos Polymeropoulos, President and CEO of Vanda Pharmaceuticals, reports acquiring additional shares of common stock.

Vanda Pharmaceuticals' CEO, Mihael Hristos Polymeropoulos, purchased 20,000 shares of common stock at an average price of $4.2236 on May 16, 2025.

Mihael Hristos Polymeropoulos, President and CEO of Vanda Pharmaceuticals, recently purchased 10,000 shares of the company's common stock.